Selective serotonin reuptake inhibitors and gastrointestinal bleeding: a case-control study
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/21736
Ficheiros no ítem
Metadatos do ítem
Título: | Selective serotonin reuptake inhibitors and gastrointestinal bleeding: a case-control study |
Autor/a: | Carvajal, Alfonso Ortega, Sara Olmo, Lourdes del Vidal, Xavier Aguirre, Carmelo Ruiz, Borja Conforti, Anita Leone, Roberto López Vázquez, Paula María Figueiras Guzmán, Adolfo Ibáñez, Luisa |
Centro/Departamento: | Universidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina |
Data: | 2011 |
Editor: | PLOS |
Cita bibliográfica: | Carvajal A, Ortega S, Del Olmo L, Vidal X, Aguirre C, Ruiz B, et al. (2011) Selective Serotonin Reuptake Inhibitors and Gastrointestinal Bleeding: A Case-Control Study. PLoS ONE 6(5): e19819. https://doi.org/10.1371/journal.pone.0019819 |
Resumo: | Background: Selective serotonin reuptake inhibitors (SSRIs) have been associated with upper gastrointestinal (GI) bleeding. Given their worldwide use, even small risks account for a large number of cases. This study has been conducted with carefully collected information to further investigate the relationship between SSRIs and upper GI bleeding. Methods: We conducted a case-control study in hospitals in Spain and in Italy. Cases were patients aged ≥18 years with a primary diagnosis of acute upper GI bleeding diagnosed by endoscopy; three controls were matched by sex, age, date of admission (within 3 months) and hospital among patients who were admitted for elective surgery for non-painful disorders. Exposures to SSRIs, other antidepressants and other drugs were defined as any use of these drugs in the 7 days before the day on which upper gastrointestinal bleeding started (index day). Results: 581 cases of upper GI bleeding and 1358 controls were considered eligible for the study; no differences in age or sex distribution were observed between cases and controls after matching. Overall, 4.0% of the cases and 3.3% of controls used an SSRI antidepressant in the week before the index day. No significant risk of upper GI bleeding was encountered for SSRI antidepressants (adjusted odds ratio, 1.06, 95% CI, 0.57–1.96) or for whichever other grouping of antidepressants. Conclusions: The results of this case-control study showed no significant increase in upper GI bleeding with SSRIs and provide good evidence that the magnitude of any increase in risk is not greater than 2. |
Versión do editor: | https://doi.org/10.1371/journal.pone.0019819 |
URI: | http://hdl.handle.net/10347/21736 |
DOI: | 10.1371/journal.pone.0019819 |
E-ISSN: | 1932-6203 |
Dereitos: | © 2011 Carvajal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited |
Coleccións
-
- PRSP-Artigos [373]